Galmed Pharmaceuticals (GLMD) Short Interest Ratio & Short Volume $1.28 -0.02 (-1.54%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.39%) As of 05/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galmed Pharmaceuticals Short Interest DataGalmed Pharmaceuticals (GLMD) has a short interest of 96,400 shares, representing 4.34% of the float (the number of shares available for trading by the public). This marks a 41.35% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest96,400 sharesPrevious Short Interest68,200 sharesChange Vs. Previous Month+41.35%Dollar Volume Sold Short$135,924.00Short Interest Ratio0.1 Days to CoverLast Record DateApril 15, 2025Outstanding Shares1,654,000 sharesFloat Size2,220,000 sharesShort Percent of Float4.34%Today's Trading Volume375,624 sharesAverage Trading Volume1,157,782 sharesToday's Volume Vs. Average32% Short Selling Galmed Pharmaceuticals? Sign up to receive the latest short interest report for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGLMD Short Interest Over TimeGLMD Days to Cover Over TimeGLMD Percentage of Float Shorted Over Time Galmed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202596,400 shares $135,924.00 +41.4%4.3%0.1 $1.41 3/31/202568,200 shares $98,208.00 +40.6%3.1%0.1 $1.44 3/15/202548,500 shares $83,754.65 +889.8%3.0%0.1 $1.73 2/28/20254,900 shares $10,652.60 +19.5%0.3%0.1 $2.17 2/15/20254,100 shares $10,496.00 -39.7%0.3%0.1 $2.56 1/31/20256,800 shares $19,074.00 +13.3%0.4%0.2 $2.81 1/15/20256,000 shares $16,740.00 -41.2%0.4%0.1 $2.79 12/31/202410,200 shares $32,538.00 -31.1%0.6%0.1 $3.19 12/15/202414,800 shares $43,956.00 -35.1%0.9%0.1 $2.97 11/30/202422,800 shares $65,208.00 +31.0%1.4%0 $2.86 Get the Latest News and Ratings for GLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/202417,400 shares $50,982.00 -62.1%1.1%0 $2.93 10/31/202445,900 shares $153,306.00 +73.9%3.1%0 $3.34 10/15/202426,400 shares $103,488.00 -22.8%1.8%0 $3.92 9/30/202434,200 shares $234,612.00 +9.6%2.3%0 $6.86 9/15/202431,200 shares $128,232.00 -23.2%5.0%0 $4.11 8/31/202440,600 shares $137,228.00 +235.5%6.6%0.8 $3.38 8/15/202412,100 shares $3,628.79 +17.5%0.2%0 $0.30 7/31/202410,300 shares $3,166.22 +14.4%0.2%0.2 $0.31 7/15/20249,000 shares $2,723.40 +1,185.7%0.2%0.2 $0.30 6/30/2024700 shares $192.50 -94.9%0.0%0 $0.28 6/15/202413,700 shares $4,557.99 -42.4%0.2%0.1 $0.33 5/31/202423,800 shares $8,808.38 -67.3%0.4%0.1 $0.37 5/15/202472,800 shares $27,918.80 -13.1%1.3%0.4 $0.38 4/30/202483,800 shares $29,497.60 +6.1%1.5%0.4 $0.35 4/15/202479,000 shares $30,012.10 +101.5%2.2%0.4 $0.38 3/31/202439,200 shares $13,574.96 +532.3%1.1%0.2 $0.35 3/15/20246,200 shares $1,891.62 -84.9%0.2%0 $0.31 2/29/202441,000 shares $16,322.10 -46.1%1.2%0.4 $0.40 2/15/202476,000 shares $28,887.60 +560.9%2.1%0.6 $0.38 1/31/202411,500 shares $4,311.35 -79.1%0.3%0.1 $0.37 1/15/202455,100 shares $25,015.40 -9.7%1.5%0.3 $0.45 12/31/202361,000 shares $27,755.00 +65.3%1.7%0.4 $0.46 12/15/202336,900 shares $13,165.92 -56.9%1.0%0.2 $0.36 11/30/202385,700 shares $30,423.50 +564.3%2.4%0.4 $0.36 11/15/202312,900 shares $5,160.00 +17.3%0.4%0.1 $0.40 10/31/202311,000 shares $4,180.00 -1.8%0.3%0.2 $0.38 10/15/202311,200 shares $4,592.00 +75.0%0.3%0.1 $0.41 9/30/20236,400 shares $3,968.00 +88.2%0.2%0 $0.62 9/15/20233,400 shares $2,515.66 -52.8%0.1%0 $0.74 8/31/20237,200 shares $5,824.80 -32.7%0.2%0 $0.81Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 8/15/202310,700 shares $8,669.14 -61.1%0.3%0 $0.81 7/31/202327,500 shares $31,625.00 -92.3%1.5%0.1 $1.15 7/15/2023357,100 shares $517,795.00 +2,668.2%20.1%1.3 $1.45 6/30/202312,900 shares $37,539.00 -6.5%0.9%0.1 $2.91 6/15/202313,800 shares $51,474.00 -14.3%1.0%0.5 $3.73 5/31/202316,100 shares $74,221.00 -18.7%1.1%0.7 $4.61 5/15/202319,800 shares $0.00 +1,700.0%1.4%0.9 $0.00 4/30/202317,200 shares $5,332.00 -6.5%0.1%0.1 $0.31 4/15/202318,400 shares $5,704.00 -30.3%0.1%0.3 $0.31 3/31/202326,400 shares $11,259.60 -28.5%0.1%0.3 $0.43 3/15/202336,900 shares $17,239.68 +58.4%0.2%0.3 $0.47 2/28/202323,300 shares $11,184.00 -32.1%0.1%0.2 $0.48 2/15/202334,300 shares $20,923.00 +106.6%0.2%0.2 $0.61 1/31/202316,600 shares $10,974.26 -88.4%0.1%0.1 $0.66 1/15/2023143,500 shares $115,058.30 -2.3%0.7%1.1 $0.80 12/30/2022146,900 shares $73,450.00 +57.3%0.7%1.3 $0.50 12/15/202293,400 shares $27,086.00 +233.6%0.4%1.1 $0.29 11/30/202228,000 shares $8,173.20 +53.0%0.1%0.8 $0.29 11/15/202218,300 shares $6,101.22 -45.9%0.1%0.4 $0.33 10/31/202233,800 shares $12,847.38 +80.8%0.2%0.6 $0.38 10/15/202218,700 shares $7,264.95 +22.2%0.1%0.3 $0.39 9/30/202215,300 shares $4,759.59 -57.5%0.1%0.2 $0.31 9/15/202236,000 shares $16,563.60 -35.5%0.2%0.4 $0.46 8/31/202255,800 shares $25,896.78 +234.1%0.3%0.5 $0.46 8/15/202216,700 shares $7,424.82 -34.0%0.1%0.2 $0.44 7/31/202225,300 shares $12,703.13 -29.3%0.1%0.2 $0.50 7/15/202235,800 shares $21,651.84 -66.4%0.2%0.3 $0.60 6/30/2022106,600 shares $69,290.00 -0.7%0.5%0.9 $0.65 6/15/2022107,300 shares $48,285.00 +364.5%0.5%1.1 $0.45 5/31/202223,100 shares $11,817.96 -0.4%0.1%0.2 $0.51 5/15/202223,200 shares $14,105.60 -27.3%0.1%0.3 $0.61 4/30/202231,900 shares $52,954.00 -37.6%0.2%0.4 $1.66 4/15/202251,100 shares $83,293.00 -6.2%0.2%0.9 $1.63 3/31/202254,500 shares $86,655.00 -47.3%0.3%0.5 $1.59 3/15/2022103,500 shares $127,305.00 -36.0%0.5%0.8 $1.23 2/28/2022161,700 shares $232,848.00 -30.9%0.8%1.2 $1.44 2/15/2022234,100 shares $374,560.00 -17.9%1.1%1.7 $1.60 1/31/2022285,200 shares $462,024.00 +21.7%1.3%1.8 $1.62 1/15/2022234,300 shares $374,880.00 +20.5%N/A1.3 $1.60 12/31/2021194,400 shares $353,808.00 -36.4%1.0%1.1 $1.82 12/15/2021305,500 shares $653,770.00 +7.0%1.5%2.5 $2.14 11/30/2021285,600 shares $719,712.00 -15.6%1.4%2.4 $2.52 11/15/2021338,500 shares $1.01 million +24.6%1.7%2.7 $2.98 10/29/2021271,700 shares $671,099.00 -16.9%1.3%2.2 $2.47 10/15/2021326,900 shares $898,975.00 +2.7%1.6%1.4 $2.75 9/30/2021318,300 shares $888,057.00 -17.0%1.6%1.4 $2.79 9/15/2021383,700 shares $1.12 million -10.8%1.9%1.6 $2.91 8/31/2021430,100 shares $1.41 million -8.0%2.1%1.7 $3.27 8/13/2021467,500 shares $1.38 million -28.5%2.3%1.4 $2.95 7/30/2021654,000 shares $1.63 million +0.8%3.3%1.8 $2.49Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 7/15/2021648,700 shares $1.69 million -0.6%3.2%2.4 $2.61 6/30/2021652,500 shares $1.98 million +23.6%3.3%2.3 $3.04 6/15/2021527,900 shares $1.68 million +97.9%2.6%1.8 $3.18 5/28/2021266,800 shares $693,680.00 -1.4%1.3%0.8 $2.60 5/14/2021270,700 shares $606,368.00 -16.4%1.4%1 $2.24 4/30/2021323,900 shares $1.09 million -2.4%1.6%0.8 $3.37 4/15/2021331,700 shares $1.09 million +15.1%1.7%0.8 $3.30 3/31/2021288,300 shares $960,039.00 +30.2%1.5%0.7 $3.33 3/15/2021221,500 shares $775,250.00 +14.8%1.1%0.5 $3.50 2/26/2021192,900 shares $792,819.00 +389.6%1.1%0.5 $4.11 2/12/202139,400 shares $212,760.00 +4.2%0.2%0.1 $5.40 1/29/202137,800 shares $142,695.00 +49.4%0.2%0.2 $3.78 1/15/202125,300 shares $88,044.00 -22.6%0.2%0.2 $3.48 12/31/202032,700 shares $106,929.00 +26.3%0.2%0.3 $3.27 12/15/202025,900 shares $94,794.00 -29.0%0.2%0.3 $3.66 11/30/202036,500 shares $152,205.00 +55.3%0.2%0.5 $4.17 11/15/202023,500 shares $79,665.00 +109.8%0.2%0.3 $3.39 10/30/202011,200 shares $34,384.00 -49.6%0.1%0.2 $3.07 10/15/202022,200 shares $74,370.00 -53.0%0.1%0.3 $3.35 9/30/202047,200 shares $166,616.00 -28.9%0.3%0.5 $3.53 9/15/202066,400 shares $278,880.00 -65.2%0.4%0.8 $4.20 8/31/2020191,000 shares $932,080.00 -56.7%1.2%2.3 $4.88 8/14/2020441,500 shares $2.09 million -3.0%2.8%5.1 $4.74 7/31/2020455,100 shares $2.21 million -2.5%2.9%4.6 $4.85 7/15/2020466,700 shares $2.20 million +0.3%3.2%5.2 $4.72 6/30/2020465,500 shares $2.25 million +23.8%3.2%5.8 $4.84 6/15/2020376,000 shares $1.85 million +1.1%2.5%4.5 $4.92 5/29/2020372,000 shares $1.77 million -4.6%2.5%4 $4.75 5/15/2020389,900 shares $1.98 million +3.5%2.6%4 $5.09 GLMD Short Interest - Frequently Asked Questions What is Galmed Pharmaceuticals' current short interest? Short interest is the volume of Galmed Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 96,400 shares of GLMD short. 4.34% of Galmed Pharmaceuticals' shares are currently sold short. Learn More on Galmed Pharmaceuticals' current short interest. Which institutional investors are shorting Galmed Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Galmed Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Galmed Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.34% of Galmed Pharmaceuticals' floating shares are currently sold short. Is Galmed Pharmaceuticals' short interest increasing or decreasing? Galmed Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 96,400 shares, an increase of 41.3% from the previous total of 68,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Galmed Pharmaceuticals' float size? Galmed Pharmaceuticals currently has issued a total of 1,654,000 shares. Some of Galmed Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Galmed Pharmaceuticals currently has a public float of 2,220,000 shares. How does Galmed Pharmaceuticals' short interest compare to its competitors? 4.34% of Galmed Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Galmed Pharmaceuticals: Traws Pharma, Inc. (2.06%), HCW Biologics Inc. (1.33%), Kiora Pharmaceuticals, Inc. (1.16%), Talphera, Inc. (1.13%), Ainos, Inc. (86.75%), Acurx Pharmaceuticals, Inc. (2.15%), BioCardia, Inc. (1.08%), Aprea Therapeutics, Inc. (1.25%), Carisma Therapeutics, Inc. (1.60%), PharmaCyte Biotech, Inc. (0.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Galmed Pharmaceuticals stock? Short selling GLMD is an investing strategy that aims to generate trading profit from Galmed Pharmaceuticals as its price is falling. GLMD shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Galmed Pharmaceuticals? A short squeeze for Galmed Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GLMD, which in turn drives the price of the stock up even further. How often is Galmed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GLMD, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Traws Pharma Short Interest Data HCW Biologics Short Interest Data Kiora Pharmaceuticals Short Interest Data Talphera Short Interest Data Ainos Short Interest Data Acurx Pharmaceuticals Short Interest Data BioCardia Short Interest Data Aprea Therapeutics Short Interest Data Carisma Therapeutics Short Interest Data PharmaCyte Biotech Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GLMD) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
